Pembrolizumab plus AVD for classical Hodgkin lymphoma, targeting the CD40/CD40-ligand axis in Waldenström Macroglobulinemia, and CXCR4-expressing CAR-cytokine induced killer cells in AML
Blood Podcast
00:00
The Role of CXCR4 in CAR T-Cell Therapy in AML
The ability of CAR T-cells to persist, or home, in the bone marrow microenvironment is a prerequisite for consistent therapeutic activity in AML. Boon marrow trials are currently underway employing chemokine receptors CCR4 and CXCR4 to improve CAR T-cell trafficking to the tumor site. The binding of CX CR4 to CXCL12 plays an important role in the retention of hematopoietic stem cells and progenitor cells in the Bone Marrow.
Transcript
Play full episode
